Avience Biomedicals
- Market cap
- ₹ 132 Cr.
- P/E
- 17x
- P/B
- 3.18x
- 52-week range
- 222 – 414.95
- ROE
- 32%
- ROCE
- 27%
- Dividend yield
- 0%
- Debt / equity
- 0.92
- Sector
- Healthcare Equipment & Supplies
- Industry
- Medical Equipment & Supplies
- Listed on
- NSE
About
Avience Biomedicals Limited is an India-based medical consumables company. The Company is focused on manufacturing of in vitro-diagnostic (IVD) products and medical devices in Noida, Uttar Pradesh, India. Its diversified product portfolio can primarily be divided into two main categories: manufacturing of medical consumables, and distribution of branded equipment. Its product categories include rapid cards, biochemistry, molecular, hematology, biochemistry regent, oxygen concentrator, culture media, plastic ware, cleaning solution, and other lab equipment. Its rapid test kit products include Avisure Pregnancy Card, Avisure Dengue Ns1 Antigen Rapid Test Kit, and Avisure Malaria Antigen Pf Pan Rapid Test Kit. Its molecular test products include H1N1 Swine Flu, and Covid Detection Kit. Its culture media products include Avienbio Chocolate Agar Plate, and Avienbio Cled Agar Bottle. Its electrolyte reagents include Avienbio Ez-Cleanser 10ml and Avienbio Multi Biosensor Module Av 80.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Medical Equipment & Supplies: 25 companies →Avience Biomedicals against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)17 against a typical 28.7: cheaper than most peers (1st = cheapest).5th of 25
- Share price, 3 months+5% against a typical −7.9%.7th of 23
- Size₹ 131.6 Cr. market value against a typical ₹ 238.1 Cr. (1st = largest).15th of 24
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 7 Sep 2026 | Other business matters | To consider other business matters: To consider and approve the Notice of the ensuing AGM, Board s Report along with the requisite annexures for the financial year ended March 31, 2026. |
| 25 Aug 2026 | Financial Results/Other business matters | To consider and approve the revised consolidated financial results for the period ended March 31, 2026 and other business matters |
| 16 Jul 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 13 Jul 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 24 | 27 | 26 |
| Expenses | 18 | 20 | 18 |
| Operating Profit | 7 | 7 | 8 |
| OPM % | 27% | 27% | 29.9% |
| Other Income | 0 | 0 | 0 |
| Interest | 1 | 1 | 1 |
| Depreciation | 0 | 1 | 1 |
| Profit before tax | 6 | 6 | 6 |
| Tax % | 27.6% | 25.7% | 33.8% |
| Net Profit | 4 | 5 | 4 |
| EPS in Rs | 10.59 | 11.26 | 10.47 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- 17%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- 22%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 38%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Avience Biomedicals | ₹ 270.90 | ₹ 132 Cr. | 17x | 3.2x | 32% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 35.2x | 5.1x | — | 19.8% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 93.9x | 14.7x | — | 26.1% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 70.9x | 18.7x | — | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21x | 4.2x | — | 15.7% |
| Laurus Labs | ₹ 1,974.00 | ₹ 1,06,658 Cr. | 124.5x | 21x | — | 15% |
Management
- Dharam Deo Choudhary
- Executive Chairman of the Board, Managing Director
- Saurabh Verma
- Chief Financial Officer
- Manoj Kumar
- Company Secretary, Compliance Officer
- Deepa Choudhary
- Executive Director
- Ram Nagina Choudhary
- Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.